Corporate Symposia - CME

 

Aiming at the Amyloid Cascade: Upstream, Downstream, and the Complexities In Between

Tuesday, July 24 | 6 p.m. – 8 p.m.

Marriott Marquis Hotel, Great Lakes Ballroom ABCD

As several compounds targeting amyloid beta have failed to demonstrate a significant clinical and/or biomarker change, many aspects of the amyloid hypothesis are being reevaluated. These include the optimal timing for intervention, drug targets, patient population, potential need for multiple interventions (both upstream and downstream), and clinical trials’ design.

Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.

This live activity is supported through an independent educational grant from Lilly.

Sponsored by: Lilly

RSVP



Become an ISTAART Member

Members of this professional society stay connected to the field through exclusive member benefits and programs. Join for just $30* at the Alzheimer's Association (Booth 301).

*Offer available onsite at AAIC (through 7/26/18). Applies only to registrants who paid the non-member fee.

Join Today

Join the Conversation #AAIC18

Follow

Exhibitors

Exhibitors

Sponsors

Sponsorship

> 1200px
lg
> 992px
md
> 768px
sm
< 767px
xs